SECUKINUMAB IMPROVES MINIMAL DISEASE ACTIVITY RESPONSE RATES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE RANDOMIZED PHASE 3 STUDY, FUTURE 2

被引：4
|
作者：
Coates, L. C. [1 ,2 ]
Mease, P. [3 ]
Kirkham, B. [4 ]
McLeod, L. D. [5 ]
Mpofu, S. [6 ]
Karyekar, C. [7 ]
Gandhi, K. [7 ]
机构：
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] Leeds Teaching Hosp NHS Trust, Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England
[3] Univ Washington, Seattle, WA 98195 USA
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] RTI Hlth Solut, Res Triangle Pk, NC USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.3949
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0463
引用
收藏
页码：605 / 605
页数：1
相关论文
共 50 条
  • [41] Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study
    Anna Campanati
    Federico Diotallevi
    Giulia Radi
    Elisa Molinelli
    Valerio Brisigotti
    Emanuela Martina
    Matteo Paolinelli
    Tommaso Bianchelli
    Cristiano Covi
    Marta Bartezaghi
    Annamaria Offidani
    European Journal of Dermatology, 2021, 31 : 630 - 637
  • [42] Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
    Strand, Vibeke
    Mease, Philip
    Gossec, Laure
    Elkayam, Ori
    van den Bosch, Filip
    Zuazo, James
    Pricop, Luminita
    Mpofu, Shephard
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 203 - 207
  • [43] SECUKINUMAB IS EFFECTIVE IN REDUCING DACTYLITIS AND ENTHESITIS USING MULTIPLE MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 2)
    Kirkham, B.
    McInnes, I. B.
    Mease, P.
    Kremer, J.
    Kandala, S.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 351 - 351
  • [44] SECUKINUMAB PROVIDES SUSTAINED REMISSION AND LOW DISEASE ACTIVITY RELATED TO DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS: TWO YEAR RESULTS FROM THE FUTURE 2 STUDY
    Mclnnes, Lain
    Smolen, Josef S.
    Kvien, Tore K.
    Pricop, Luminita
    Fox, Todd
    Rasouliyan, Lawrence
    Jugl, Steffen
    Gaillez, Corine
    RHEUMATOLOGY, 2018, 57
  • [45] SECUKINUMAB PROVIDES RAPID AND SUSTAINED REDUCTIONS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DATA FROM THE PHASE 3 RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED FUTURE 2 STUDY
    Kirkham, Bruce
    Mease, Philip J.
    McInnes, Iain B.
    RHEUMATOLOGY, 2017, 56 : 77 - 77
  • [46] Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
    Kirkham, Bruce
    Nash, Peter
    Navarra, Sandra
    Quebe-Fehling, Erhard
    Gaillez, Corine
    Sastre, Carlos
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [47] Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
    van der Heijde, Desiree
    Mease, Philip J.
    Landewe, Robert B. M.
    Rahman, Proton
    Tahir, Hasan
    Singhal, Atul
    Boettcher, Elke
    Navarra, Sandra
    Zhu, Xuan
    Ligozio, Gregory
    Readie, Aimee
    Mpofu, Shephard
    Pricop, Luminita
    RHEUMATOLOGY, 2020, 59 (06) : 1325 - 1333
  • [48] Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
    Kivitz, Alan J.
    Kremer, Joel M.
    Legerton III, Clarence W.
    Pricop, Luminita
    Singhal, Atul
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 675 - 689
  • [49] SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS
    Mease, Philip
    Kirkham, Bruce
    Nash, Peter
    Balsa, Alejandro
    Combe, Bernard
    Rech, Juergen
    Martin, Ruvie
    Ligozio, Gregory
    Abrams, Ken
    Pricop, Luminita
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 15 - 16
  • [50] Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
    Mease, Philip
    van der Heijde, Desiree
    Landewe, Robert
    Mpofu, Shephard
    Rahman, Proton
    Tahir, Hasan
    Singhal, Atul
    Boettcher, Elke
    Navarra, Sandra
    Meiser, Karin
    Readie, Aimee
    Pricop, Luminita
    Abrams, Ken
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (06) : 890 - 897
12345